Sign inJoin waitlistJoin the waitlist

Ankit Mangla

Co-Director, Sarcoma and Cutaneous Oncology Team · UH Seidman Cancer Center

Credentials: · · · · · ·

History

Sarcoma and Cutaneous Oncology Team · UH Seidman Cancer Center
Present
CWRU School of Medicine
Present
CWRU School of Medicine
Present

John H Stroger, Jr Hospital Of Cook County
2015–2018
John H Stroger, Jr Hospital Of Cook County
2012–2015
Armed Forces Medical College, Maharashtra University Of Health Sciences
2007

Research

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 2023 · 739 citations
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living…
Journal of Clinical Oncology · 2023 · 65 citations
Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Network Open · 2022 · Last of 9 authors · Corresponding · 49 citations

Luke Rothermel
23 papers
Richard Hoehn
17 papers · 1 as a fellow
IS
Iris Sheng
13 papers
Nikki Agarwal
13 papers · 9 as a resident
HK
Hanna Kakish
12 papers · 11 as a resident
Jeremy Bordeaux
10 papers
Maira Bhatty
7 papers · 4 as a resident
HS
Hailey Seibert
6 papers · 4 as a resident
Natalie Chakraborty
6 papers · 6 as a resident
Trisha Lal
6 papers · 6 as a resident
Jarred Boone
5 papers · 5 as a resident
John Ammori
5 papers

Clinical trials

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
Principal investigator · Recruiting · Phase 1, Phase 2
Ankit Mangla, MD
2026–2028
Actinium Therapy for Late-stage Aggressive Sarcomas
Site PI · Recruiting · Phase 1
Ratio Therapeutics, Inc.
2025–2032
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2021–2027